Inlexzo J Code: J9183

Drug & Product Overview

HCPCS Descriptor Gemcitabine intravesical system, 225 mg

HCPCS Added Date April 1, 2026

Manufacturer Janssen

Route of Administration Intravesical

Generic Status Single-Source; Branded

Dosage Form System

About Inlexzo

Inlexzo is a medication aligned to the HCPCS J Code: J9183 for billing, pricing, and reimbursement purposes in the United States. This Oncology medication is administered via the intravesical route and manufactured by Janssen.

Manufacturers, reach out to us to add more information.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
57894-0225-01	Inlexzo	Janssen Biotech, Inc	1	225 MG

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

Inlexzo Pricing & Reimbursement

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q3 2026

Gemcitabine Intravesical 505(b)(2) Information:

HCPCS Code	Manufacturer	Active Ingredient	HCPCS Description
J9183	Janssen	Gemcitabine Intravesical	Gemcitabine intravesical system, 225 mg

Inlexzo Claims Performance

Claims from Jan 2026 – Aug 2026

Claim Denial Rate 0%

Avg. Days to File 3.0days

Avg. Days to Pay 18.5days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore J9183 claims analytics on FocalPoint →

Inlexzo CPT Administration Codes

CPT Code	Description
51720	Bladder instillation of anticarcinogenic agent, including retention time

Not on the CMS JW / JZ list

This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers. Wastage billing guide →

Inlexzo Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

BCG-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors

Drug Class

Nucleic Acid Synthesis Inhibitors [MoA]Nucleoside Metabolic Inhibitor [EPC]

Frequently Asked Questions

Is there an available Inlexzo billing and coding guide?

Billing and coding information for Inlexzo can be found through Janssen Biotech, Inc.. Visit Here →

Are there any available Inlexzo patient assistance programs?

Inlexzo patient assistance information can be found through Janssen. Visit Here →

Where can I find Inlexzo prescribing information?

Inlexzo prescribing information can be found at the link below. Visit Here →

Where can I find Inlexzo side effect information?

Information regarding Inlexzo's side effects can be found at MedlinePlus. Visit Here →

Does billing Inlexzo require JZ/JW wastage modifiers?

This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.